Unique ID issued by UMIN | UMIN000045484 |
---|---|
Receipt number | R000051884 |
Scientific Title | A Study to Assess the Eye Moisturizing Effects of Enzymatic Decomposed Rooster Comb (INJUV(TM)) Oral Intake in Human |
Date of disclosure of the study information | 2021/09/15 |
Last modified on | 2022/01/13 10:36:44 |
A Study to Assess the Eye Moisturizing Effects of Enzymatic Decomposed Rooster Comb (INJUV(TM)) Oral Intake in Human
A Study to Assess the Eye Moisturizing Effects of Enzymatic Decomposed Rooster Comb (INJUV(TM)) Oral Intake in Human
A Study to Assess the Eye Moisturizing Effects of Enzymatic Decomposed Rooster Comb (INJUV(TM)) Oral Intake in Human
A Study to Assess the Eye Moisturizing Effects of Enzymatic Decomposed Rooster Comb (INJUV(TM)) Oral Intake in Human
Japan |
N/A (healthy adults)
Adult |
Others
NO
The purpose of this study is to assess the improvement effects on eye moisturization by oral intake of enzymatic decomposed rooster comb (INJUV(TM)) in human.
Safety,Efficacy
DEQS,Visual Analogue Scale,BUT(Tear film break-up time),Schirmer's test
Visual acuity examination, Intraocular pressure examination,Refraction inspection,Anti-aging QOL common questionnaire
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Food |
Oral intake of the test product (4 weeks)
20 | years-old | <= |
60 | years-old | > |
Male and Female
[1]Japanese males and females aged 20-59 years
[2]Healthy individuals without chronic diseases, including eye and skin disorders
[3]Individuals who have dry eye like symptoms in their daily lives (tired eyes, rough eyes, eye dry feeling, discomfort in eyes, tingling in eyes, red eyes, difficulty in opening eyes in the morning, crumpled eyes, etc.)
[4]Individuals who works with VDT (Visual Display Terminals) for 5 days or more a week (in total 20 hours or more a week including video games, PC and mobile phone operation time)
[5]Individuals with corrected visual acuity of 1.0 or higher who are not wearing contact lenses or who can change to eyeglasses during the study period
[6]Individuals voluntarily to join the study with written informed consent
[7]Individuals who can visit study site and receive examinations on designated days
[8]Individuals judged appropriate to join this study by principal investigators
[1]Individuals receiving medical drugs for treatment of chronic diseases
[2]Individuals receiving/received medical drug treatment for the past 1 month except for temporary relief medication such as headache, menstrual pain, common cold, etc.
[3]Individuals under treatment or with history of mental disorders, sleep disorders, hypertension, diabetes, lipid metabolism abnormality, or other serious disorders
[4]Individuals with history of serious diseases (hepatic, renal, cardiovascular, respiratory, hematologic, etc.)
[5]Individuals with history of gastrointestinal disorders except for appendicitis
[6]Individuals who use artificial tears (eye drops) 6 times or more a day
[7]Individuals diagnosed with presbyopia or aware of presbyopia
[8]Individuals with eye disease, entropion of the eyelids, trichiasis
[9]Individuals with a definitive diagnosis of dry eye
[10]Individuals using eye drops to treat eye diseases
[11]Individuals with refractive error and not properly corrected
[12]Individuals undergoing LASIK surgery
[13]Individuals with severe astigmatism
[14]Individuals who are thought to have eye strain due to dysregulation such as neurosis
[15]Individuals with >=30.0kg/m2 BMI
[16]Individuals with drug or food allergies
[17]Individuals who have a habit of continuing to take functional foods, health foods, and supplements for the purpose of improving eye function, or who plan to take them during the study period, now and within the past 3 months
[18]Individuals who are currently or within the last 3 months taking health foods containing enzymatic decomposed rooster combs, hyaluronic acid, collagen, proteoglycans, elastin, or their precursors during the study period or individuals planning to take new those products
[19]Individuals with alcohol intake exceeding 60g/day
[20]Individuals who may significantly change their lifestyle during the study period
[21]Individuals who work at night
etc.
12
1st name | Yoshikazu |
Middle name | |
Last name | Yonei |
Faculty of Life and Medical Sciences,Doshisha University
Anti-Aging Medical Research Center
6100394
1-3 Tatara Miyakodani,Kyotanabe City,Kyoto
0774-65-6394
yyonei@mail.doshisha.ac.jp
1st name | Toshiyasu |
Middle name | |
Last name | Tamura |
TES Holdings Co., Ltd.
Department of Clinical Trial
1100015
6F,Kairaku Bldg,2-7-5 Higashi-Ueno,Taitou-ku,Tokyo
03-6801-8400
info@tes-h.co.jp
LAIMU Corporation
LAIMU Corporation
Profit organization
Society of Glycative Stress Research
5F-11,Musashino Bldg,2-13-10 Shinjuku,Shinjuku-ku,Tokyo
03-6709-8842
rinri-glycativestress@antiaging-bank.com
NO
うえのあさがおクリニック
2021 | Year | 09 | Month | 15 | Day |
Unpublished
Completed
2021 | Year | 08 | Month | 31 | Day |
2021 | Year | 09 | Month | 10 | Day |
2021 | Year | 09 | Month | 21 | Day |
2021 | Year | 12 | Month | 04 | Day |
2021 | Year | 12 | Month | 05 | Day |
2021 | Year | 12 | Month | 17 | Day |
2021 | Year | 12 | Month | 20 | Day |
2021 | Year | 09 | Month | 14 | Day |
2022 | Year | 01 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051884